METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Clinical trials for METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug VYLOY under Real-World watch for advanced stomach cancer in korea
Disease control Recruiting nowThis study follows 377 people in South Korea with advanced stomach or food-pipe cancer that cannot be removed by surgery or has spread. They receive VYLOY as part of their normal care. The main goal is to track side effects and see how long the cancer stays stable in everyday med…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Sponsor: Astellas Pharma Korea, Inc. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New hope for stomach cancer: early access drug targets key protein
Disease control AVAILABLEThis program provides early access to zolbetuximab, a drug that targets a protein called claudin18.2 found on some stomach cancer cells. It is for people with advanced stomach or gastroesophageal junction cancer that has not been treated yet. Participants receive zolbetuximab plu…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Triple therapy shows promise in Hard-to-Treat stomach cancer
Disease control Recruiting nowThis study tests whether adding zolbetuximab to standard immunotherapy (pembrolizumab) and chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. The trial enrolls 500 adults whose tumors have specific proteins (CLDN18.2 and PD-L1) but la…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 01, 2026 16:01 UTC